MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
More news: Software
Written by / Agency / Source: Oracle Corporation
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Oracle Invests in Proteus Digital Health and its FDA-Approved Ingestible Sensor Platform - Digital Health Feedback System Will Allow Oracle’s Clinical Trial Applications Customers Exclusive Access to Real-time Data on Therapeutic Use to Dramatically Improve Clinical Trial Efficiency (NASDAQ: ORCL) - ProteusDigitalHealth.com / Oracle.com
Oracle Invests in Proteus Digital Health and its FDA-Approved Ingestible Sensor Platform

 

NewswireToday - /newswire/ - Redwood Shores, CA, United States, 2013/05/01 - Digital Health Feedback System Will Allow Oracle’s Clinical Trial Applications Customers Exclusive Access to Real-time Data on Therapeutic Use to Dramatically Improve Clinical Trial Efficiency (NASDAQ: ORCL) - ProteusDigitalHealth.com / Oracle.com. NYSE, NASDAQ: ORCL

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Software Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Oracle and Proteus Digital Health announced today that Oracle has made a strategic minority investment in Proteus, a leading digital health company.

Proteus has developed ingestible and wearable sensors that have FDA approval and are marketed as medical devices in the United States and Europe. Proteus has over 500 patents and patent applications on digital health technologies and their uses pending or issued in the U.S. and other countries.

Proteus Digital Health is working to create a new category of products called Digital Medicines. In these products, pharmaceuticals will be manufactured with the FDA approved ingestible sensor inside. Upon ingestion the sensor will communicate with a wearable sensor on the skin. The wearable sensor also captures the body’s physiologic responses and behaviors, and sends the digital health information to a mobile application. The Proteus system is designed to deliver precise information about medication ingestion, dose timing and associated physiologic response of patients, including heart rate, activity, rest, and skin temperature. Digital Medicines are under development by Proteus and its pharmaceutical partners and require additional regulatory approvals.

In conjunction with this investment, Oracle and Proteus expect to work together in clinical trials exclusively to provide clinical investigators worldwide the ability to measure information about medication ingestion, dose timing, and associated physiologic response continuously and precisely for patients enrolled in clinical trials.

The two companies are expected to integrate Proteus’ ingestible sensor with Oracle’s leading clinical trial products, such as Oracle Health Sciences InForm, Oracle Life Sciences Data Hub and Oracle’s Siebel Clinical Trial Management System, using the secure, reliable and scalable Oracle Health Sciences Cloud.

Clinical trial sponsors, service providers, investigators and patients worldwide are expected to benefit from continuous, precise and near real-time information about when a dose of medicine under clinical investigation is actually ingested by a patient and the associated physiological responses. These unique insights into medication adherence and patient response will support more efficient clinical trial strategies, including adaptive trials and real world clinical trials.

Financial details of the investment and the strategic partnership were not disclosed.

Supporting Quotes
“To optimize the clinical development of personalized, innovative and safe therapies, clinical trial sponsors, clinical trial service providers, investigators and patients worldwide require continuous, precise and near real-time information on what medicines are taken and the patient’s physiological response when inside and outside of a clinical setting,” said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences Global Business Unit. “We are looking forward to integrating Proteus’ technology into Oracle’s cloud-based clinical trial platform to provide these unique benefits to the industry.”

“The relationship of two innovative leaders like Oracle and Proteus will provide life sciences companies and contract research organizations (CROs) with a unique capability to more effectively conduct clinical trials,” said Andrew Thompson, President, CEO and co-founder, Proteus Digital Health. “Oracle’s global scale, broad clinical trial platform, deep domain knowledge and resources for clinical trials will be combined with our in-depth expertise and leading position in integrated ingestion-based technology, providing the industry with a complete and robust solution to help improve human health.”

About Oracle
Oracle engineers hardware and software to work together in the cloud and in your data center.

About Oracle in Industries
Oracle industry solutions leverage the company's best-in-class portfolio of products to address complex business processes relevant to health sciences, helping speed time to market, reduce costs, and gain a competitive edge.

About Oracle Health Sciences
At Oracle, we believe that a more predictive, preventive, personalized and participatory system will help improve human health. We can help accelerate this journey to personalized medicine through technology, data and insights. Oracle's solutions support industry initiatives to improve care quality and outcomes, reduce costs, and speed time to market for new treatments, therapies and devices. Oracle Health Sciences delivers comprehensive business applications, plus database, middleware, and hardware solutions for life sciences and healthcare companies and institutions worldwide.

About Proteus Digital Health
Proteus Digital Health (proteusdigitalhealth.com) is pioneering a new category of products, services and data systems based on ingestible sensing. Its core technology the digital health feedback system provides an unprecedented view into an individual’s personal health choices and physiologic response, allowing patients to better manage their health and more effectively collaborate with caregivers and clinicians, while enabling new information-based business models. Proteus has received a CE mark in Europe and FDA market clearance in the U.S. for its wearable and ingestible sensor devices. Headquartered in Redwood City, Calif., Proteus is privately held and funded by Carlyle, Essex Woodlands, Kaiser Permanente, Medtronic, Novartis, Otsuka, ON Semiconductor and other investors.

Trademark
Oracle and Java are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.

Contact: Robin Suchan, Proteus Digital Health
P: 415-946-1055 - E: rsuchan[.]wcgworld.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Software Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Oracle Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
Software Warnings - IMPORTANT:
Always be aware/cautious about what you download on your computer/mobile! PURCHASE SOFTWARE related keywords / Banner Ads. Click HERE for details!
.

 
  Your Banner Ad showing on ALL
Software articles,
CATCH Visitors via Your Competitors Announcements!


Oracle Invests in Proteus Digital Health and its FDA-Approved Ingestible Sensor Platform

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Greg Lunsford - Oracle.com 
650-506-6523 greg.lunsford[.]oracle.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Oracle Corporation securities in any jurisdiction including any other companies listed or named in this release.

Software via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Oracle Corporation / Company Profile


Read Software Most Recent Related Newswires:

Aptean and MYJAR Named 2020 Credit Excellence Award Winners
WANdisco Announces Global Agreement with Infosys to De-Risk and Accelerate Data Lake Migration to the Cloud
Veeva and Bioforum Partner with RedHill Biopharma to Maximize Value of Opaganib Phase 2/3 COVID-19 Clinical Data
The Rutland Group Selects Yardi Voyager to Streamline Operations
AccessData Announces the Release of New Quin-C User Interface
UN Global Compact in Partnership with Accenture and SAP, and with 3M Launch SDG Ambition Guidance to Accelerate Business Action to Achieve the SDGs
TIBCO 2020 Partner Excellence Awards Recognize Partner Innovation
Turbonomic Unveils the Next Generation Platform for the Modern Application Era
Veeva Commercial Cloud Selected by Idorsia to Accelerate Digital Engagement Globally
Nebbiolo Technologies Named as Leading Industrial IoT Edge Platform - North America Frost & Sullivan Customer Value Leadership Awards Report
Yardi Named Again to Prestigious Forbes Cloud 100 List
WANdisco Democratizes Data Lake Migration to the Cloud with the Launch of LiveData Migrator
Medair Selects Visionet Deutschland GmbH as Global IT Partner
Acceleware Announces Grant of Key RF XL Patent
MOL Group Chooses SAP Ariba Solutions to Digitalize Global Procurement

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Huntington Study Group Ltd





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)